Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient

被引:0
|
作者
Franceschini, Gianluca [1 ]
Di Leone, Alba [1 ]
Sanchez, Alejandro Martin [1 ]
D'Archi, Sabatino [1 ]
Terribile, Daniela [1 ]
Magno, Stefano [1 ]
Scardina, Lorenzo [1 ]
Masetti, Riccardo [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli, Dept Woman Child & Publ Hlth, IRCCS,Div Breast Surg, Largo Agostino Gemelli 8, I-00168 Rome, Italy
关键词
Axillary treatment; Breast cancer; Neoadjuvant chemotherapy; Sentinel lymph node biopsy; AXILLARY DISSECTION; MANAGEMENT;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Today, sentinel lymph node biopsy (SLNB) is considered the gold standard for axillary staging in early breast cancer patients with clinically negative lymph nodes (cNO). SLNB allows to determine the axillary lymph node status sparing the axillary dissection (AD) and its potential complications (seroma formation, loss of sensation, shoulder dysfunction and lymphedema) On the other hand, SLNB for nodal staging in breast cancer patients with clinically negative lymph nodes after neoadjuvant chemotherapy (ycN0) is a highly debated topic due to different reported success rates. In order to optimize oncological results, high identification rate (> 90%) and false negative rate as low as possible (< 10%) should always be obtained when performing SLNB after neoadjuvant chemotherapy. The success rates of SLNB after neoadjuvant chemotherapy (NAC) mainly depend on the clinical lymph node status pre-NAC. In patients with pre-NAC clinically negative nodes (cN0) and at restaging with post-NAC clinically negative nodes (ycN0), SLNB after chemotherapy should be performed because it is an accurate and safe procedure. In patients with pre-NAC clinically positive nodes (cN+) and at restaging with post-NAC clinically negative nodes (ycN0), SLNB after chemotherapy might be considered thanks to the high lymph nodal pathologic complete response rate; however, in this last setting, individual ability, technical skills and repetitive performance of specific tasks must always be followed to improve the identification rate and false negative rate. AD may be avoided only if sentinel lymph node is negative [ypN0(sn)J; instead, to date, patients with metastatic sentinel lymph node after neoadjuvant chemotherapy, even with only isolated tumor cells, fypN+(sn) including ypN0i+(sn) and ypN1mic(sn)J should always be treated with AD. However, NAC significantly increases the difficulties and complexity of axillary surgical management. A personalized multidisciplinary path in specialized breast centers should ensure an accurate clinical counselling and refined patient selection for SLNB post-NAC.
引用
收藏
页码:465 / 468
页数:4
相关论文
共 50 条
  • [31] Sentinel lymph node biopsy in patients with locally advanced breast cancer after neoadjuvant chemotherapy
    Walter Aguiar, Paulo Henrique
    Porto Pinheiro, Luiz Gonzaga
    Salani Mota, Rosa Maria
    Gurjao Margotti, Nair Hermnia
    Xavier Rocha, Joao Ivo
    ACTA CIRURGICA BRASILEIRA, 2012, 27 (12) : 912 - 916
  • [32] Axillary and internal mammary sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy
    Cao, Xiao-Shan
    Li, Hui-Juan
    Cong, Bin-Bin
    Sun, Xiao
    Qiu, Peng-Fei
    Liu, Yan-Bing
    Wang, Chun-Jian
    Wang, Yong-Sheng
    ONCOTARGET, 2016, 7 (45) : 74074 - 74081
  • [33] Sentinel lymph node biopsy is feasible for breast cancer patients after neoadjuvant chemotherapy.
    Kinoshita T.
    Breast Cancer, 2007, 14 (1) : 10 - 15
  • [34] Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer
    Stephanie M. Wong
    Mark Basik
    Livia Florianova
    Richard Margolese
    Sinziana Dumitra
    Thierry Muanza
    Annie Carbonneau
    Cristiano Ferrario
    Jean Francois Boileau
    Annals of Surgical Oncology, 2021, 28 : 2621 - 2629
  • [35] Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy. A pilot study
    Piato, JRM
    Barros, ACSD
    Pincerato, KM
    Sampaio, APQ
    Pinotti, JA
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (02): : 118 - 120
  • [36] Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Carcinoma of the Breast
    Schwartz, Gordon F.
    Tannebaum, Jonathan E.
    Jernigan, Amelia M.
    Palazzo, Juan P.
    CANCER, 2010, 116 (05) : 1243 - 1251
  • [37] SENTINEL LYMPH NODE BIOPSY IN BREAST CANCER AFTER NEOADJUVANT CHEMOTHERAPPY
    Hadidane, M.
    Slimane, M.
    Henchiri, H.
    Sakhri, S.
    Laamouri, B.
    Bouzaiene, H.
    Ben Hassouna, J.
    Rahal, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 112 - 112
  • [38] Repeat axillary sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive sentinel lymph node at presentation
    Aroui, T.
    Rebollo, A. C.
    Sanchez, R.
    Gallego, M.
    Testart, N.
    Garcia, J.
    Menjon, S.
    Llamas, J. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S359 - S359
  • [39] SENTINEL LYMPH NODE BIOPSY IN BREAST CANCER AFTER NEOADJUVANT CHEMOTHERAPPY
    Hadidane, M.
    Slimane, M.
    Henchiri, H.
    Sakhri, S.
    Laamouri, B.
    Bouzaiene, H.
    Ben Hassouna, J.
    Rahal, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 622 - 622
  • [40] Sentinel Lymph Node Biopsy in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
    Pecha, Vaclav
    Kolarik, Dusan
    Kozevnikova, Renata
    Hovorkova, Karolina
    Hrabetova, Petruse
    Halaska, Michael
    Sottner, Oldrich
    Trnkova, Marketa
    Petruzelka, Lubos
    Kolarova, Hana
    CANCER, 2011, 117 (20) : 4606 - 4616